Big-bucks first quarter masks drop in deal volume
Bristol-Myers Squibb’s $74bn bid for Celgene led to a huge quarter, but a drop in the deal count could give pause to those hoping for a bumper year.
Following the M&A money, by phase and therapy area
A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets, while buyers remain most interested…
Big pharma consolidation: the tectonic plates shift
The takeover of Celgene has disrupted pharma’s conventional wisdom on which companies should merge and when. This is how things now stand.
As takeover hopes build, 2018 provides a low bar to beat
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
Medtechs saw little advantage in scale in 2018
Big medtech is keeping its purse-strings closed – but private equity sees value in subsidiaries.
Few biopharma buyouts in quiet third quarter
The $6.6bn of M&A deals announced by drug makers in third quarter of 2018 marks the slowest three-month period since 2013.
Shikeda masks slow second quarter for buyouts
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.